Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Recs

0
Player Avatar TruffelPig (< 20) Submitted: 11/10/2011 9:21:04 PM : Outperform Start Price: $3.30 SNTA Score: +23.50

Many Phase II and one Phase III ongoing on multiple small molecule drugs against cancer and inflammatory disease. Harvard/MIT scientists. Promising data.

Featured Broker Partners


Advertisement